Please assess the completion status of the following clinical trial:

Trial Title: Sevoflurane PharmacokInetics in ARDS

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥18 years~* Presence for ≤ 12 hours of all of the following conditions, within one week of a clinical insult or new or worsening respiratory symptoms :~a PaO2/FiO2 \< 200 mmHg with positive end-expiratory pressure (PEEP) ≥ 8 cmH2O (or, if arterial blood gas not available : SpO2/FiO2 ratio that is equivalent to a PaO2/FiO2 \< 200 mmHg with PEEP ≥8 cmH2O, and a confirmatory SpO2/FiO2 ratio between 1-6 hours after the initial SpO2/FiO2 ratio determination) b Bilateral opacities not fully explained by effusions, lobar/lung collapse, or nodules c Respiratory failure not fully explained by cardiac failure or fluid overload; need objective assessment (e.g., echocardiography) to exclude hydrostatic edema if no risk factor present~Exclusion Criteria:~* Lack of informed consent~* Continuous sedation with inhaled sevoflurane at enrollment~* Currently receiving ECMO therapy~* Chronic respiratory failure defined as PaCO2 \> 60 mmHg in the outpatient setting~* Home mechanical ventilation (non-invasive ventilation or via tracheotomy) except for CPAP/BIPAP used solely for sleep-disordered breathing~* Body mass index \> 40 kg/m2~* Chronic liver disease defined as a Child-Pugh score of 12-15~* Expected duration of mechanical ventilation \< 48 hours~* Tidal volume of 6 mL/kg predicted body weight (PBW) below 200 mL~* Decision to withhold life-sustaining treatment; except in those patients committed to full support except cardiopulmonary resuscitation~* Moribund patient, i.e. not expected to survive 24 hours despite intensive care~* Burns \> 70% total body surface~* Previous hypersensitivity or anaphylactic reaction to sevoflurane~* Medical history of malignant hyperthermia~* Suspected or proven intracranial hypertension~* Know pregnancy - Pregnancy testing will be systematically performed to rule out pregnancy in female patients of reproductive age~* Enrollment in another interventional ARDS trial with direct impact on sedation and PEEP~* Endotracheal ventilation for greater than 120 hours (5 days)~* PaO2/FiO2 (if available) \> 200 mmHg after meeting inclusion criteria and before start of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nonfocal ARDS (Type: EXPERIMENTAL): ARDS patient with nonfocal lung imaging phenotype
- Focal ARDS (Type: EXPERIMENTAL): ARDS patient with focal lung imaging phenotype

Based on this trial design, predict the completion outcome and termination type (if applicable).